GHO Capital Invests in Cell Therapy CDMO RoslinCT

Global Healthcare Opportunities, or GHO Capital Partners LLP, a European specialist investor, has invested in RoslinCT, a Contract Development and Manufacturing Organization (CDMO) focused on advanced cell therapies.
 
Established in 2006 in Edinburgh, Scotland, with support from Scottish Enterprise, RoslinCT was formed through an initial spin-out from the Roslin Institute, which has a famous track record in genetic and cellular biology.
 
Since 2014, the company has had a manufacturing base within the University of Edinburgh’s Centre for Regenerative Medicine in a facility shared with the Scottish National Blood Transfusion Service. RoslinCT has worked to advance the field of regenerative medicine and today is at the forefront of high-quality cell therapy development and manufacturing. The company recently expanded into facilities at the Edinburgh BioQuarter, and is recognized globally as a unique CDMO establishing its own commercial scale production.
 
RoslinCT services an established, international customer base of blue-chip Pharma and Biotech companies, partnering from development phase through to late-stage clinical manufacturing. The business is set to benefit from exponential growth in the advanced therapy market which is forecast to grow at up to 50% annually.
 
With GHO’s backing, RoslinCT will significantly increase its development and manufacturing capacity, supporting customer acquisition and product diversification.
 
RoslinCT will benefit from GHO’s sector expertise and international resources to accelerate growth, scaling the business to build on its best-in-class therapies and better service a growing international client base.
 
The Partners at GHO Capital commented, “RoslinCT is renowned for its best-in-class services in developing and manufacturing advanced cell therapies and we are delighted to partner with the team. With an established background in regenerative medicines and a strong foothold in Scotland as the leading center for cell therapy research, RoslinCT, with our investment and specialist expertise, is uniquely positioned to drive the next stage of its growth. We look forward to realizing the shared ambition for RoslinCT become a global CDMO with commercialized cell therapy manufacturing capabilities.”
 
Janet Downie of RoslinCT said, “Having built RoslinCT and our highly skilled team over many years I am delighted to have the support of GHO. GHO have a wealth of healthcare expertise which is key, as we look to drive global growth and expand our operations to meet rising international demand. With huge advancements being made in the cell therapy industry, RoslinCT is now perfectly positioned to truly become a global CDMO, having gone from strength to strength in recent years. I see this as a very natural and exciting step for the business and we look forward to hitting further milestones with the backing of GHO.”
 
Malcolm Bateman, CEO Roslin Foundation, added, “I’m delighted to recognize the success of the company that I, along with colleagues at the Roslin Institute, created back in 2006. The Roslin Foundation have enjoyed working with the excellent team at RoslinCT over the years. This is a fantastic success story and we are confident that the company, in partnership with GHO, will continue to set the standard for high quality cell therapy manufacturing. We wish everyone involved all the best for the future.”
 
Slaughter & May acted as legal advisor to GHO, and Alvarez and Marsal acted as both financial and tax advisor, Deloitte as structuring advisor, ClearView Healthcare Partners as commercial advisor, Dark Horse Consulting Group as Technical advisor and ERM as ESG advisor.
 
Torreya Partners (Europe) LLP served as financial advisor to RoslinCT and Dentons provided legal advice.